A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Conditions:   PTLD;   Lymphoid Tumor;   Hematopoietic/Lymphoid Cancer;   Plasmacytic Hyperplasia PTLD;   Infectious Mononucleosis;   Florid Follicular Hyperplasia PTLD;   Polymorphic PTLD;   Monomorphic PTLD;   Classical Hodgkin Lymphoma Type PTLD Interventions:   Drug: Rituximab;   Drug: Brentuximab Vedotin;   Drug: Bendamustine Sponsors:   Francesca Montanari;   Mayo Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials